Financial Report: Catalent

Catalent

4Q Revenues: $532.2 million (+4%)

4Q Earnings: $58.1 million (earnings were $153.5 million 4Q15)

FY Revenues: $1.9 billion (+1%)

FY Earnings: $111.2 million (-47%)

Comments: Revenue from the Softgel Technologies segment was $224.8 million for the quarter, up 1%. Revenue from the Drug Delivery Solutions segment was $238.2 million, an increase of 9%, primarily driven by increased volumes for fee-for-service development work and analytical testing in the U.S., and increased volumes related to biologics and blow-fill-seal offerings. Revenue from the Clinical Supply Services segment was $81.5 million in the quarter, up 1%. Results were impacted by the temporary suspension of operations at the company’s facility in Beinheim, France, which occurred between November 2015 and April 2016.